Current Cancer Drug Targets
Title:Editorial: Multiple Myeloma Immunotherapies
Volume: 17 Issue: 9
Author(s): Klaus Podar
Affiliation:
Export Options
About this article
Cite this article as:
Podar Klaus , Editorial: Multiple Myeloma Immunotherapies, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/156800961709171005160041
DOI https://dx.doi.org/10.2174/156800961709171005160041 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
22
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Neglected Diseases Caused By Bacterial Infections
Current Medicinal Chemistry Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry The Influence of Inflammatory Cytokines on the Proliferation and Osteoblastic Differentiation of MSCs
Current Stem Cell Research & Therapy Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Current Topics in Medicinal Chemistry Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Advanced Development Strategies for Biopharmaceutical Cell Culture Processes
Current Pharmaceutical Biotechnology The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets